Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
9.86
-0.42 (-4.09%)
At close: Jun 2, 2026, 4:00 PM EDT
9.90
+0.04 (0.41%)
After-hours: Jun 2, 2026, 4:00 PM EDT
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $516.00K in the quarter ending March 31, 2026, a decrease of -99.47%. This brings the company's revenue in the last twelve months to $23.14M, down -88.41% year-over-year. In the year 2025, Atara Biotherapeutics had annual revenue of $120.77M, down -6.33%.
Revenue (ttm)
$23.14M
Revenue Growth
-88.41%
P/S Ratio
3.78
Revenue / Employee
$1,652,786
Employees
14
Market Cap
83.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 120.77M | -8.17M | -6.33% |
| Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
| Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
| Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
| Dec 31, 2021 | 20.34M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 66.16M |
| ImmuCell | 29.93M |
| Pelthos Therapeutics | 27.70M |
| MindWalk Holdings | 20.70M |
| NeurAxis | 4.28M |
| Rani Therapeutics Holdings | 3.17M |
| Rallybio | 858.00K |
ATRA News
- 15 days ago - Atara Biotherapeutics upgraded to Hold from Sell at Freedom Broker - TheFly
- 20 days ago - Atara Biotherapeutics reports Q1 EPS -29c, consensus -22c - TheFly
- 21 days ago - Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress - Business Wire
- 21 days ago - Atara Biotherapeutics Quarterly report: Q1 2026 - Filings
- 21 days ago - Atara Biotherapeutics Earnings release: Q1 2026 - Filings
- 25 days ago - Atara Biotherapeutics upgraded to Buy from Hold at Canaccord - TheFly
- 26 days ago - Atara Biotherapeutics trading halted, volatility trading pause - TheFly
- 26 days ago - Atara Biotherapeutics jumps 70%, or $3.60, to $8.75 - TheFly